Pipeline Expansion Agomab is advancing a broad clinical pipeline across fibro-inflammation targets, including Phase 2b programs for FSCD and IPF. This presents cross-disease upsell opportunities with CROs, biotech partners, and large pharma for co-development, licensing, or strategic collaborations to accelerate portfolio breadth.

Regulatory Progress Regulatory alignment with FDA on NOV-ERA Phase 2b design and novel endpoints signals credible clinical strategy and potential faster de-risking. This creates conversations for regulatory consulting, investigator networks, and potential milestone-driven partnerships with sponsors seeking efficient pathways.

Financial Backing Recent IPO proceeds and cash runway into mid-2029 indicate financial momentum and readiness for late-stage trials and expanded trials. This can attract collaboration talks with manufacturers, contract research organizations, and finance-led partnerships for milestone-sharing or asset monetization.

Key Programs Ontunisertib and AGMB-447 occupy core positions with Fast Track and Orphan Drug designations, signaling large addressable markets. Opportunities exist to engage in companion diagnostics, patient stratification services, and co-development deals with specialty pharma focusing on Crohn’s disease and IPF.

Industry Interest Active investor and conference engagement, including FDA interactions and open AGM transparency, indicate high visibility to the biotech investment community and potential strategic buyers. Leverage this exposure to initiate partnership dialogues, licensing negotiations, and joint development forums with interested industry players.